<DOC>
	<DOCNO>NCT01368003</DOCNO>
	<brief_summary>In research study , investigator look determine safety efficacy investigational drug , STA9090 alone combination dutasteride treatment castrate resistant prostate cancer . STA9090 may cause growth cancer slow shrink target protein require cancer grow . The investigator also look determine whether use dutasteride lower male hormone level enhance effect STA9090 treatment castrate resistant prostate cancer .</brief_summary>
	<brief_title>STA-9090 Castration-Resistant Prostate Cancer With Assessment Androgen Receptor Pathway Signaling</brief_title>
	<detailed_description>Subjects tumor biopsy treatment begin . Subjects randomize Arm A receive infusion STA9090 day 1 , 8 , 15 28 day cycle . Subjects randomize Arm B receive daily oral dutasteride 2 week prior begin STA9090 treatment . They continue receive dutasteride study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Adenocarcinoma prostate Progressive castration resistant disease Metastatic disease Normal organ marrow function History current coronary artery disease , myocardial infarction , angina pectoris , angioplasty coronary bypass Current treatment follow antiarrhythmic drug : flecainide , moricizine propafenone New York Heart Association class II/III/IV congestive heart failure Current prior radiation therapy leave hemithorax Treatment chronic immunosuppressant Uncontrolled intercurrent illness Poor venous access study drug administration Venous thromboembolism past 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Castration resistant prostate cancer</keyword>
</DOC>